---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-073937"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2025-04-07T23:59:59+00:00"
generated_at: "2026-05-23T19:42:01.804750+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Viridian appoints Jeff Ajer to board; grants stock options to 14 new employees

## Summary
- Jeff Ajer, former BioMarin CCO with 25+ years rare disease experience, appointed to VRDN board effective April 7, 2025.
- Ajer led launches of 5 brands at BioMarin; will support veligrotug BLA submission and potential commercial launch.
- Compensation Committee approved inducement grants of options for 220,750 shares to 14 new employees on April 1, 2025.
- Options vest over 4 years (25% at one-year anniversary, then monthly), exercise price equals closing price on grant date.
- Appointment strengthens board as Viridian advances veligrotug and FcRn portfolio toward regulatory milestones.

## SEC filing metadata
- accession: 0001193125-25-073937
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2025-04-07T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312525073937/0001193125-25-073937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312525073937/d875125d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-073937
- JSON: https://secwatch.observer/filing/0001193125-25-073937.json
- Plain text: https://secwatch.observer/filing/0001193125-25-073937.txt

## Key facts
- Executive change
  Jeff Ajer was appointed as Director at Viridian Therapeutics, Inc.\DE.
  - Action: appointed
  - Role: Director
  source text: On April 2, 2025, the Board of Directors (the “Board”) of Viridian Therapeutics, Inc. (the “Company”), appointed Jeff Ajer to serve as a Class I director of the Company, effective as of April 7, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312525073937/0001193125-25-073937-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.